about
The Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia TherapyERG transcriptional networks in primary acute leukemia cells implicate a role for ERG in deregulated kinase signalingResistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphomaAn oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cellsRegulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell linesCharacteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical modelmTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.Short-Term PTEN Inhibition Improves In Vitro Activation of Primordial Follicles, Preserves Follicular Viability, and Restores AMH Levels in Cryopreserved Ovarian Tissue From Cancer PatientsRedeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain productionDown-regulation of the PI3K/Akt signaling pathway and induction of apoptosis in CA46 Burkitt lymphoma cells by baicalin.Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy.Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia.miR-340 Inhibits Proliferation and Induces Apoptosis in Gastric Cancer Cell Line SGC-7901, Possibly via the AKT Pathway.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma.Control of B lymphocyte development and functions by the mTOR signaling pathways.MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen.The Role of mTOR Inhibitors for the Treatment of B-Cell LymphomasmTOR signaling: new networks for ALL.mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.
P2860
Q26799596-ACB1ED25-51BD-438E-9A29-CCDB0D804674Q28484833-9D1574A3-A013-4012-9AFA-D3BAD9565F98Q28540038-724DC070-C452-420C-8F90-CA4349B55066Q33429430-394C43A0-38CF-4DDF-8385-99CFC7DB3EDDQ33433009-5E452832-18D9-4AFF-8D21-687F730ED503Q33442621-72F78E6C-1890-47FF-80E3-A61EC24EFF5CQ33706877-CAB79C95-C7CB-420D-AC61-11C8B487D09EQ33709439-2B95E5AB-0C78-4D91-98B0-64C314C284CCQ34673267-3A4E259C-AC59-46F0-818D-91B7A6A93B99Q34732945-E6C67B51-91E9-4011-9D95-96FB0BB69C2FQ35176311-47C7073E-E977-45CA-962D-F2F22B55AF51Q35273390-E415F66C-9225-4E9D-AF80-AF7C3711AC66Q35646371-49346DE0-1B84-4A2A-A093-C261790788E8Q35664315-8F6ABACA-C964-4C4E-9FC9-990717144E52Q36112720-40635841-F786-45E1-811C-6724F6DA1123Q36607050-155E6178-4051-4746-9E6B-2622A4B5A2AFQ36673421-048901D4-1A29-4759-A71C-2F8F007AF0C7Q37588157-A3D04089-6612-4828-8D95-EB29BA6645FCQ37643136-85CAB289-D485-4643-ADE0-D78CC4DCF9E8Q38097334-1F95C0EC-BB1F-4294-A5AB-8136AC2CF2FDQ38218128-477D7121-0AC2-4C87-8DAB-5858FCDBD624Q38311896-CAF25CB3-9BFC-41D0-B8C4-EF501F463946Q38674507-546B55DA-62CD-46BA-A811-FA0A356B3949Q39218802-B822976C-83A5-4ACE-8886-F2872CEBCB59Q41909242-BB5AEC25-A760-4671-A018-3D5D8AE992D9Q42743076-0C48C6F2-B8FF-4CCF-B45C-71EC89BE63D5Q49787386-6D0C55E8-4145-4CEB-9111-9BFE8C56B3AA
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Target of rapamycin signaling in leukemia and lymphoma.
@en
Target of rapamycin signaling in leukemia and lymphoma.
@nl
type
label
Target of rapamycin signaling in leukemia and lymphoma.
@en
Target of rapamycin signaling in leukemia and lymphoma.
@nl
prefLabel
Target of rapamycin signaling in leukemia and lymphoma.
@en
Target of rapamycin signaling in leukemia and lymphoma.
@nl
P1476
Target of rapamycin signaling in leukemia and lymphoma.
@en
P2093
David A Fruman
P304
P356
10.1158/1078-0432.CCR-10-0480
P407
P577
2010-09-08T00:00:00Z